991 research outputs found

    Eliminating Scale Drift in Monocular SLAM Using Depth from Defocus

    Full text link
    © 2017 IEEE. This letter presents a novel approach to correct errors caused by accumulated scale drift in monocular SLAM. It is shown that the metric scale can be estimated using information gathered through monocular SLAM and image blur due to defocus. A nonlinear least squares optimization problem is formulated to integrate depth estimates from defocus to monocular SLAM. An algorithm to process the output keyframe and feature location estimates generated by a monocular SLAM algorithm to correct for scale drift at selected local regions of the environment is presented. The proposed algorithm is experimentally evaluated by processing the output of ORB-SLAM to obtain accurate metric scale maps from a monocular camera without any prior knowledge about the scene

    Monocular 3D metric scale reconstruction using depth from defocus and image velocity

    Full text link
    © 2017 IEEE. This paper presents a novel approach to metric scale reconstruction of a three-dimensional (3D) scene using a monocular camera. Using a sequence of images from a monocular camera with a fixed focus lens, metric distance to a set of features in the environment is estimated from image blur due to defocus. The blur texture ambiguity which causes scale errors in depth from defocus is corrected in an EKF framework that exploits image velocity measurements. We show in real experiments that our method converges to a metric scale, accurate, sparse depth map and 3D camera poses with images from a monocular camera. Therefore, the proposed approach has the potential to enhance robot navigation algorithms that rely on monocular cameras

    Fast transform decoding of nonsystematic Reed-Solomon codes

    Get PDF
    A Reed-Solomon (RS) code is considered to be a special case of a redundant residue polynomial (RRP) code, and a fast transform decoding algorithm to correct both errors and erasures is presented. This decoding scheme is an improvement of the decoding algorithm for the RRP code suggested by Shiozaki and Nishida, and can be realized readily on very large scale integration chips

    Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles

    Get PDF
    OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size
    corecore